SCHEMBL4722113

SCHEMBL4722113

Nc1ncnc2scc(C(=O)Nc3cccc(NC(=O)Nc4ccc(F)cc4)c3)c12

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MARK3 P27448 10/20 0.78
STK3 Q13188 10/20 0.78
PLK4 O00444 9/20 0.78
MAP4K4 O95819 9/20 0.78
AXL P30530 9/20 0.78
MAP4K2 Q12851 9/20 0.78
SLK Q9H2G2 9/20 0.78
MKNK2 Q9HBH9 9/20 0.78
MARK2 Q7KZI7 9/20 0.78
LCK P06239 9/20 0.78
BLK P51451 9/20 0.78
MINK1 Q8N4C8 8/20 0.78
CDK1 P06493 8/20 0.78
LIMK1 P53667 8/20 0.78
CLK4 Q9HAZ1 8/20 0.78
BRSK1 Q8TDC3 7/20 0.78
MET P08581 7/20 0.78
MAP4K5 Q9Y4K4 7/20 0.78
CSNK1G2 P78368 7/20 0.78
CAMK2G Q13555 7/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4721626 0.94 STK3 (0.78) MARK3STK3PLK4MAP4K4AXL
SCHEMBL4761640 0.94 PLK4 (0.81) MARK3STK3PLK4MAP4K4AXL
SCHEMBL5472182 0.93 STK3 (0.73) MARK3STK3PLK4MAP4K4AXL
SCHEMBL4721372 0.92 PLK4 (0.89) MARK3STK3PLK4MAP4K4AXL
SCHEMBL4720555 0.90 PLK4 (0.89) MARK3STK3PLK4MAP4K4AXL
SCHEMBL5478260 0.88 PLK4 (1.00) MARK3STK3PLK4MAP4K4AXL
SCHEMBL4719761 0.88 PLK4 (1.00) MARK3STK3PLK4MAP4K4AXL
SCHEMBL4721391 0.88 PLK4 (0.78) MARK3STK3PLK4MAP4K4AXL
SCHEMBL5474997 0.88 MAP4K4 (0.74) MARK3STK3PLK4MAP4K4AXL
SCHEMBL4720107 0.87 MAP4K4 (0.74) MARK3STK3PLK4MAP4K4AXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1968979-A2 9-MEMBERED HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PROTEIN KINASES ABBOTT LABORATORIES (US) 2008-09-17 EP disclosed
WO-2007067781-A2 9-MEMBERED HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PROTEIN KINASES ABBOTT LABORATORIES (US) 2007-06-14 WO disclosed
US-20070135387-A1 Inhibitors of protein kinases ABBOTT LABORATORIES 2007-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135387-A1 Inhibitors of protein kinases MAP3K20, PACSIN2, MAP4K2 MARK3 402/4885STK3 237/4885PLK4 230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.